雙相情感障礙市場規模、佔有率、成長分析，按類型、按藥物類別、按分銷管道、按地區 - 行業預測，2025 年至 2032 年

2023 年全球雙極性情感障礙市場規模價值53.6 億美元，預計將從2024 年的54.9 億美元成長到2032 年的66.4 億美元，預計在預測期內（2025-2032 年）的複合年成長率為1.2 %。

憂鬱症，現稱為雙極性情感障礙，其特徵是情緒波動劇烈，包括躁症和憂鬱症發作。遺傳易感性在疾病中起著重要作用，涉及多個基因而不是單一的致病因素。雙極性情感障礙主要有三種：雙極 I 型、雙相 II 型和週期性障礙。有趣的是，印度人一生中罹患躁鬱症的風險僅為 0.1%，而美國則高得多，達到 4.4%。由於宣傳活動的不斷加強、精準情緒評估技術的進步以及發病率的上升，雙相情感障礙治療市場正在不斷擴大。此外，由於副作用，三環抗憂鬱藥物的使用正在減少，從而轉向更有效的治療選擇。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 客戶和購買標準分析

雙極性情感障礙市場規模（按類型）

• 市場概況
• 情緒穩定劑
• 抗驚厥藥
• 抗精神病藥物
• 抗憂鬱症
• 抗焦慮藥物
• 其他類型

雙極性情感障礙市場規模（依藥物類別）

• 市場概況
• 選擇性血清素再回收抑制劑
• 血清素正腎上腺素再回收抑制劑
• 三環抗憂鬱藥物
• 單胺氧化酵素抑制劑
• 苯二氮平類
• BETA受體阻斷劑
• 其他藥物類別

雙極性情感障礙市場規模（按分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

雙極性情感障礙市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Eli Lilly and Company（USA）
• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• AstraZeneca plc（UK）
• Otsuka Holdings Co., Ltd.（Japan）
• H. Lundbeck A/S（Denmark）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Novartis International AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• Alkermes plc（Ireland）
• Mylan NV（USA）
• Neurocrine Biosciences, Inc.（USA）
• Vanda Pharmaceuticals Inc.（USA）
• Sunovion Pharmaceuticals Inc.（USA）
• Intra-Cellular Therapies, Inc.（USA）
• Acadia Pharmaceuticals Inc.（USA）
• Reviva Pharmaceuticals Holdings, Inc.（USA）

結論和建議

Global Bipolar Disorder Market size was valued at USD 5.36 billion in 2023 and is poised to grow from USD 5.49 billion in 2024 to USD 6.64 billion by 2032, growing at a CAGR of 2.4% during the forecast period (2025-2032).

Manic depression, now known as bipolar disorder, is characterized by extreme mood fluctuations, including manic and depressive episodes. Genetic predisposition plays a significant role in this condition, with multiple genes involved rather than a single causative factor. There are three main types of bipolar disorder: bipolar I, bipolar II, and cyclothymic disorder. Interestingly, while India's lifetime risk for bipolar disorder is just 0.1%, the United States has a significantly higher prevalence at 4.4%. The market for bipolar disorder treatment is expanding, driven by increasing awareness campaigns, advancements in technology for accurate mood assessment, and the rising incidence of the disorder. Additionally, the use of tricyclic antidepressants is declining due to their side effects, leading to a shift toward more effective treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bipolar Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bipolar Disorder Market Segmental Analysis

Global Bipolar Disorder Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Mood stabilizer, Anticonvulsants, Antipsychotic drugs, Antidepressant drugs, Antianxiety drugs and Other Types. Based on Drug Class, the market is segmented into Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor, Tricyclic antidepressant drugs, Monoamine oxidase inhibitors, Benzodiazepines, Beta blockers and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bipolar Disorder Market

The global bipolar disorder market is expected to witness significant growth driven by a strong focus on enhancing product offerings and an increasing prevalence of mental health issues. Key players in the industry are actively expanding their product portfolios, which includes the introduction and approval of new pharmaceuticals specifically targeting bipolar disorder. For instance, the FDA recently approved Allergan plc and Gedeon Richter plc's supplemental new drug application for VRAYLAR (cariprazine), underscoring the commitment to advancing treatment options. Furthermore, rising awareness initiatives and government efforts aimed at highlighting the impacts of bipolar disorder, alongside a growing demand for effective antidepressants, are contributing to a reduction in the overall burden of this mental health condition.

Restraints in the Global Bipolar Disorder Market

The Global Bipolar Disorder market faces significant challenges due to several restraints that could impede its growth. A prominent issue is the insufficient availability of effective medications and suitable treatment protocols, which complicates management of the condition. Additionally, the expiration of patents for major drugs, such as Latuda, Abilify Maintena, and Risperdal Consta, poses further limitations, potentially leading to increased competition from generic alternatives like lithium. Moreover, the absence of reliable diagnostic methods and the adverse side effects associated with existing treatments exacerbate these market constraints. However, advancements in drug combination therapies present potential avenues for future growth within this sector.

Market Trends of the Global Bipolar Disorder Market

The global bipolar disorder market is witnessing significant growth, driven by the rising prevalence of mental health disorders, particularly among children and adolescents. Increased awareness and reduced stigma surrounding mental illnesses have led to higher diagnosis rates of bipolar disorder, prompting a surge in demand for effective treatment options. Advances in pharmacotherapy and psychotherapy, combined with the integration of digital health solutions, are further transforming the therapeutic landscape. Additionally, greater emphasis on personalized medicine and early intervention strategies is anticipated to enhance patient outcomes, solidifying bipolar disorder as a critical area within the broader mental health market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Customer & Buying Criteria Analysis

Global Bipolar Disorder Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mood stabilizer
• Anticonvulsants
• Antipsychotic drugs
• Antidepressant drugs
• Antianxiety drugs
• Other Types

Global Bipolar Disorder Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Selective serotonin reuptake inhibitor
• Serotonin norepinephrine reuptake inhibitor
• Tricyclic antidepressant drugs
• Monoamine oxidase inhibitors
• Benzodiazepines
• Beta blockers
• Other Drug Classes

Global Bipolar Disorder Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Bipolar Disorder Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations